ArticleJournal of orthopaedic translation2026
Methylene blue restores NAD
Article in Journal of orthopaedic translation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- From local tissue repair to systemic precision orthopaedics: recent advances in musculoskeletal regeneration and translational medicine.Journal of orthopaedic translation · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: NAD Methods: Published single-cell RNA sequencing data were analysed, and human Achilles tendons were harvested for histological evaluation and ex vivo explant cultures. Rat experimental tendinopathy models and primary rat tenocytes were utilized. Key outcomes included quantification of NAD Results: NAD homeostasis orchestrated metabolic and biosynthetic programming to counteract oxidative stress in tendinopathy. MB restored NAD homeostasis, enhanced ATP production, and reduced ROS accumulation, while improving collagen fiber organization. MC1 and AIF synergistically regulated NAD metabolism in AT. Rotenone (Rot) inhibited the vitality of MC1, as MB restored NAD homeostasis even under the treatment of Rot but failed to reverse oxidative stress, matrix degeneration, and reduced cell viability. In contrast, AIF deficiency induced MC1 dysfunction in AT, yet MB rescued NAD dysregulation, oxidative stress, and matrix degeneration under AIF knockdown conditions. Conclusion: We demonstrated that MB targets NAD metabolism to regulate AIF-driven mitochondrial repair, promoting MC1 biogenesis in both human and rat AT, thereby maintaining energy metabolism and redox homeostasis. Collectively, our work highlights the central role of NAD metabolism in AT pathogenesis and supports the potential of developing a therapeutic strategy targeting MB, AIF, and MC1. The translational potential of this article: Importantly, the characterization of emergent functional and mechanistic properties of MB establishes a translational paradigm for old drug repurposing, with highlighting potential for convenient clinical translation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.